Gsk Full Year Results 2025 – GSK saw core operating profit jump in Q2 and won the latest round in its ongoing legal case, making the share price look even more undervalued to me. . GSK offers promising investment opportunities in healthcare industry despite economic uncertainties and risks. Read more on GSK stock here. .

Gsk Full Year Results 2025

Source : www.gsk.com

GSK delivers 4% growth in Q2 revenue, ups full year guidance

Source : firstwordpharma.com

Events calendar | GSK

Source : www.gsk.com

EX 15.2

Source : www.sec.gov

GSK delivers strong 2023 performance and upgrades growth outlooks

Source : www.gsk.com

Meningococcal Vaccination Disparities in the U.S. Persist Across

Source : www.idse.net

Annual Report 2023 | GSK

Source : www.gsk.com

GSK cuts 2024 vaccines sales amid CDC’s narrowed RSV policy

Source : www.fiercepharma.com

GSK Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Source : finance.yahoo.com

GSK reports blockbuster sales RSV shot Arexvy in race vs. Pfizer

Source : www.fiercepharma.com

Gsk Full Year Results 2025 GSK delivers strong 2023 performance and upgrades growth outlooks : Specialty Medicines led the way with a 22% increase, bolstered by new oncology and HIV products. GSK’s overall sales were 5% ahead of consensus in the second quarter. Specialty medicines performed . London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 .